Huang Liang, Chen Xiaoyu, Wang Zhaojun
Department of Gastroenterology, Dongguan Kanghua Hospital, Dongguan, Guangdong, China.
Department of Pediatric Surgery, Jingzhou Central Hospital, The Second Clinical Medical College, Yangtze University, Jingzhou, Hubei, China.
Int J Infect Dis. 2025 Jan;150:107293. doi: 10.1016/j.ijid.2024.107293. Epub 2024 Nov 5.
This study assesses the global, regional, and national burden of hepatitis B virus (HBV) and hepatitis C virus (HCV) related to injecting drug use (IDU) from 1990 to 2021.
Data from the Global Burden of Disease Study 2021 were analyzed to quantify deaths, age-standardized mortality rates (ASMR), disability-adjusted life years (DALYs), and age-standardized DALYs rates (ASDR) due to HBV and HCV from IDU across 204 countries. Trends were evaluated using estimated annual percentage change. Analyzing the association between ASDR and SDI using a loess regression model.
From 1990 to 2021, the global burden of deaths and DALYs due to HBV and HCV attributed to IDU showed an increasing trend, especially among males, whose mortality rates were significantly higher than females. In 2021, global deaths due to HBV from IDU were 13,050.8, with an ASMR of 0.15 per 100,000 and an ASDR of 5.3, both showing an increasing trend with estimated annual percentage changes (EAPCs) of 1.09 and 0.96, respectively. HCV deaths reached 231,764.4, with an ASMR of 2.68 (EAPC: 0.38) and a relatively stable ASDR trend (EAPC: 0.01). Although raw death rates for HCV have increased, the ASMR and ASDR have remained stable or slightly declined, highlighting different trends across sexes and regions. India had the highest national deaths, while the highest ASDRs were in the Republic of Moldova (HBV) and Mongolia (HCV). South Asia recorded the highest regional deaths for both HBV and HCV. Positive correlations between ASDRs for HBV and HCV with SDI were observed.
The burden of HBV and HCV due to IDU has increased from 1990 to 2021, especially among males, with significant regional and national disparities. Targeted drug prohibition interventions and policies are needed.
本研究评估了1990年至2021年期间与注射吸毒（IDU）相关的乙型肝炎病毒（HBV）和丙型肝炎病毒（HCV）的全球、区域和国家负担。
分析了《2021年全球疾病负担研究》的数据，以量化204个国家因注射吸毒感染HBV和HCV导致的死亡人数、年龄标准化死亡率（ASMR）、伤残调整生命年（DALY）和年龄标准化DALY率（ASDR）。使用估计的年度百分比变化评估趋势。使用局部加权回归模型分析ASDR与社会人口指数（SDI）之间的关联。
1990年至2021年期间，因注射吸毒感染HBV和HCV导致的全球死亡和DALY负担呈上升趋势，尤其是在男性中，其死亡率显著高于女性。2021年，因注射吸毒感染HBV导致的全球死亡人数为13050.8人，ASMR为每10万人0.15人，ASDR为5.3，两者均呈上升趋势，估计年度百分比变化（EAPC）分别为1.09和0.96。HCV死亡人数达到231764.4人，ASMR为2.68（EAPC：0.38），ASDR趋势相对稳定（EAPC：0.01）。尽管HCV的原始死亡率有所上升，但ASMR和ASDR保持稳定或略有下降，凸显了不同性别和地区的不同趋势。印度的国家死亡人数最高，而摩尔多瓦共和国（HBV）和蒙古（HCV）的ASDR最高。南亚记录的HBV和HCV区域死亡人数均最高。观察到HBV和HCV的ASDR与SDI之间存在正相关。
1990年至2021年期间，因注射吸毒感染HBV和HCV的负担有所增加，尤其是在男性中，存在显著的区域和国家差异。需要有针对性的禁毒干预措施和政策。
